Clinical Trials

Are you an adult with heart failure and an implanted CardioMEMS pulmonary artery pressure (PAP) monitor? This study is investigating whether psychological stress can make the symptoms of heart failure worse. Participants of this study will have their blood pressure monitored and their blood drawn after undergoing mental stress in a controlled setting, within a laboratory. To participate in this study, you must be at least 18 years old. This study takes place in New Haven, Connecticut.

Do you have heart failure and need treatment with intravenous (IV) diuretics? This study is exploring the use of chloride supplementation in people with heart failure who require treatment with IV diuretics, which are used to help rid your body of excess water and salt. To participate in this study, you must have heart failure with signs of volume overload (rales, edema, elevated jugular venous pressure [JVP], or weight gain of at least 5 pounds) requiring treatment with IV diuretics. This study takes place in New Haven, Connecticut.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Have you been diagnosed with obstructive sleep apnea (OSA) and been referred to the Yale New Haven Hospital Sleep Center for continuous positive airway pressure (CPAP) treatment? This study is examining how the features that can raise or lower the risk of OSA can impact how well CPAP works in an individual. Researchers will use detailed sleep studies to determine which features contribute to OSA. Results from this study will help researchers develop treatment plans that can lead to personalized OSA treatments to improve patient lives. To participate in this study, you must be at least 19 years old. This study takes place in North Haven, Connecticut.

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

The study is to investigate that the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling during an orthostatic challenge.

Do you have a family history of high cholesterol? Researchers are studying whether a particular medication can lower cholesterol in people with a family history of high cholesterol. You may be able to participate if you are 18 to 69 years old, have not had a heart attack or stroke recently, and do not have uncontrolled high blood pressure. This study will take place in Nashville, Tennessee.

The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.

The purpose of this study is to compare reintubation rates and outcomes of patients treated with high-flow nasal canula oxygen therapy (HFNC) and patients treated with provider choice of standard care.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.